Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.
While it is well recognized that individuals with ovarian cancer who have previously responded to platinum-based therapy can achieve a second response to cisplatin or carboplatin at the time of relapse, limited data exist in the oncologic literature regarding the number of times this process can be repeated. We briefly report here three patients with ovarian cancer currently being cared for in the Gynecologic Oncology program of the Cleveland Clinic Foundation who have achieved four (1 patient) or five (2 patients) separate clinical responses to cisplatin or carboplatin-based chemotherapy and have survived >4 years since the date of first relapse. This experience emphasizes the point that platinum resistance cannot be defined based on total treatment courses or the number of prior platinum-based regimens delivered, but only by objective evidence of failure of the drugs in an individual patient.
Markman
M
M
Department of Hematology/Medical Oncology, Cleveland Clinic Cancer Center, Cleveland Clinic Foundation, Ohio 44195, USA.
Kennedy
A
A
Webster
K
K
Kulp
B
B
Peterson
G
G
Belinson
J
J
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood; D016190:Carboplatin / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy*
D000970:Antineoplastic Agents; D018394:CA-125 Antigen; D016190:Carboplatin; D002945:Cisplatin